Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study

Fig. 1

Patient disposition. A total of 606 patients were randomized into either the CT-P13 group (n = 302) or the RP group (n = 304). A total of 151 patients were withdrawn for the stated reasons. The first patient was screened in November 2010, and the last patient visit was in July 2012. RP reference product (i.e., reference infliximab)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us